These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

402 related articles for article (PubMed ID: 11424229)

  • 1. The importance of first-phase insulin secretion: implications for the therapy of type 2 diabetes mellitus.
    Del Prato S; Tiengo A
    Diabetes Metab Res Rev; 2001; 17(3):164-74. PubMed ID: 11424229
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phasic insulin release and metabolic regulation in type 2 diabetes.
    Del Prato S; Marchetti P; Bonadonna RC
    Diabetes; 2002 Feb; 51 Suppl 1():S109-16. PubMed ID: 11815468
    [TBL] [Abstract][Full Text] [Related]  

  • 3. What therapy do our NIDDM patients need? Insulin releasers.
    Crepaldi G; Del Prato S
    Diabetes Res Clin Pract; 1995 Aug; 28 Suppl():S159-65. PubMed ID: 8529509
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Control of postprandial hyperglycemia: optimal use of short-acting insulin secretagogues.
    Carroll MF; Izard A; Riboni K; Burge MR; Schade DS
    Diabetes Care; 2002 Dec; 25(12):2147-52. PubMed ID: 12453952
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical importance of insulin secretion and its interaction with insulin resistance in the treatment of type 2 diabetes mellitus and its complications.
    Porte D
    Diabetes Metab Res Rev; 2001; 17(3):181-8. PubMed ID: 11424231
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Beta- and alpha-cell dysfunction in type 2 diabetes.
    Del Prato S; Marchetti P
    Horm Metab Res; 2004; 36(11-12):775-81. PubMed ID: 15655708
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Type II diabetes mellitus.
    Edelman SV
    Adv Intern Med; 1998; 43():449-500. PubMed ID: 9506190
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mechanisms for hyperglycemia in type II diabetes mellitus: therapeutic implications for sulfonylurea treatment--an update.
    Porte D; Kahn SE
    Am J Med; 1991 Jun; 90(6A):8S-14S. PubMed ID: 1872310
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Early-phase prandial insulin secretion: its role in the pathogenesis of type 2 diabetes mellitus and its modulation by repaglinide.
    Owens DR; Cozma LS; Luzio SD
    Diabetes Nutr Metab; 2002 Dec; 15(6 Suppl):19-27. PubMed ID: 12702004
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The importance of early insulin secretion and its impact on glycaemic regulation.
    Garber AJ
    Int J Obes Relat Metab Disord; 2000 Sep; 24 Suppl 3():S32-7. PubMed ID: 11063282
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [The impact of regulation of postprandial glucose in practice].
    Vergès B
    Diabetes Metab; 1999 Dec; 25 Suppl 7():22-5. PubMed ID: 10746008
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Islet dysfunction in non-insulin-dependent diabetes mellitus.
    Kahn SE; Porte D
    Am J Med; 1988 Nov; 85(5A):4-8. PubMed ID: 3057894
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Loss of early insulin secretion leads to postprandial hyperglycaemia.
    Del Prato S
    Diabetologia; 2003 Mar; 46 Suppl 1():M2-8. PubMed ID: 12652352
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pathophysiology of insulin secretion in diabetes mellitus.
    Ward WK; Beard JC; Halter JB; Porte D
    Adv Exp Med Biol; 1985; 189():137-58. PubMed ID: 3898762
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Miglitol (BAY m 1099) treatment of diabetic hypothalamic-dietary obese rats improves islet response to glucose.
    Axen KV; Li X; Sclafani A
    Obes Res; 1999 Jan; 7(1):83-9. PubMed ID: 10023734
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pathophysiology of insulin secretion.
    Scheen AJ
    Ann Endocrinol (Paris); 2004 Feb; 65(1):29-36. PubMed ID: 15122089
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Pharmacological properties of nateglinide, rapid-onset/short-duration insulinotropic agent, in the treatment of type 2 diabetes].
    Ikenoue T; Kondo N
    Nihon Yakurigaku Zasshi; 2000 Sep; 116(3):171-80. PubMed ID: 11031747
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Importance of postprandial glucose control.
    Bell DS
    South Med J; 2001 Aug; 94(8):804-9. PubMed ID: 11549192
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Glyburide enhances the responsiveness of the beta-cell to glucose but does not correct the abnormal patterns of insulin secretion in noninsulin-dependent diabetes mellitus.
    Shapiro ET; Van Cauter E; Tillil H; Given BD; Hirsch L; Beebe C; Rubenstein AH; Polonsky KS
    J Clin Endocrinol Metab; 1989 Sep; 69(3):571-6. PubMed ID: 2503533
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacological interventions that directly stimulate or modulate insulin secretion from pancreatic beta-cell: implications for the treatment of type 2 diabetes.
    Farret A; Lugo-Garcia L; Galtier F; Gross R; Petit P
    Fundam Clin Pharmacol; 2005 Dec; 19(6):647-56. PubMed ID: 16313276
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.